Ondemand webcast of expert faculty presentation and case discussion featuring implementation strategies for practicing precision medicine to treat patients with earlystage nonsmallcell lung cancer Editors Note This live presentation was recorded on September 29 2024 On October 3 2024 the FDA approved nivolumab with platinumdoublet chemotherapy as neoadjuvant therapy followed by singleagent nivolumab after surgery as adjuvant treatment for adults with resectable NSCLC tumors 4 cm andor node positive and no known EGFR mutations or ALK rearrangements This approval was based on the results of the CheckMate77T trial
- Provider:Clinical Care Options
- Activity Link: https://clinicaloptions.com/CE-CME/oncology/precision-medicine-in-early-stage-nsclc/25440-56902
- Start Date: 2024-10-18 05:00:00
- End Date: 2024-10-18 05:00:00
- Credit Details: IPCE Credits: 0.75 hours
AMA PRA Category 1 Credit™️: 0.75 hours
Nursing: 0.75 hours
Pharmacy: 0.75 hours - Commercial Support: Source: Merck (Any division) - Amount: 25000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest